Trial Profile
A Phase I Safety and Bioimaging Trial of DS-8895a in Patients With Advanced or Metastatic EphA2 Positive Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs DS 8895 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 11 Apr 2022 Results published in the Investigational New Drugs
- 04 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
- 04 Oct 2016 Status changed from recruiting to active, no longer recruiting.